These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33035922)

  • 1. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
    Tavares MT; Kozikowski AP; Shen S
    Eur J Med Chem; 2021 Jan; 209():112887. PubMed ID: 33035922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
    Wang XX; Wan RZ; Liu ZP
    Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells.
    Ptacek J; Snajdr I; Schimer J; Kutil Z; Mikesova J; Baranova P; Havlinova B; Tueckmantel W; Majer P; Kozikowski A; Barinka C
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group.
    Linciano P; Pinzi L; Belluti S; Chianese U; Benedetti R; Moi D; Altucci L; Franchini S; Imbriano C; Sorbi C; Rastelli G
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2080-2086. PubMed ID: 34583596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Novel Histone Deacetylase 6-Selective Inhibitors Bearing 3,3,3-Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group.
    Kurohara T; Tanaka K; Takahashi D; Ueda S; Yamashita Y; Takada Y; Takeshima H; Yu S; Itoh Y; Hase K; Suzuki T
    Chembiochem; 2021 Nov; 22(22):3158-3163. PubMed ID: 34224197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC6 as privileged target in drug discovery: A perspective.
    Pulya S; Amin SA; Adhikari N; Biswas S; Jha T; Ghosh B
    Pharmacol Res; 2021 Jan; 163():105274. PubMed ID: 33171304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).
    Shen S; Kozikowski AP
    Expert Opin Ther Pat; 2020 Feb; 30(2):121-136. PubMed ID: 31865813
    [No Abstract]   [Full Text] [Related]  

  • 8. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
    Porter NJ; Mahendran A; Breslow R; Christianson DW
    Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel class of anthraquinone-based HDAC6 inhibitors.
    Song Y; Lim J; Seo YH
    Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors.
    Goracci L; Deschamps N; Randazzo GM; Petit C; Dos Santos Passos C; Carrupt PA; Simões-Pires C; Nurisso A
    Sci Rep; 2016 Jul; 6():29086. PubMed ID: 27404291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationship of thiol-based histone deacetylase 6 inhibitors.
    Guo Z; Zhang Y; Bao Y; Huang Z; Gu X; Wang G; Li J
    Chem Biol Drug Des; 2022 Jul; 100(1):90-107. PubMed ID: 35404520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
    Ruzic D; Djokovic N; Nikolic K
    Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes.
    Osko JD; Christianson DW
    Methods Enzymol; 2019; 626():447-474. PubMed ID: 31606087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction.
    Sharma C; Oh YJ; Park B; Lee S; Jeong CH; Lee S; Seo JH; Seo YH
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, Bioactivity Evaluation, Crystal Structures, and In Silico Studies of New α-Amino Amide Derivatives as Potential Histone Deacetylase 6 Inhibitors.
    Xu Y; Tang H; Xu Y; Guo J; Zhao X; Meng Q; Xiao J
    Molecules; 2022 May; 27(10):. PubMed ID: 35630812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
    Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
    J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
    Li Y; Sang S; Ren W; Pei Y; Bian Y; Chen Y; Sun H
    Eur J Med Chem; 2021 Dec; 226():113874. PubMed ID: 34619465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
    He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
    Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.